Medical Developments International Limited (MVP) Fair Value & Analysis
Healthcare · AU · Market cap A$42.8M
Fair value as of: Jun 24, 2026
From 17 valuation models · updated 5 days ago
Share price −1.3% over the past month.
Price vs Fair Value (12 months)
12‑month range A$0.3795 – A$0.7795 · fair‑value band A$0.3300 – A$0.6000 · the A$0.4000 price screens below the A$0.4400 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Medical Developments International Limited (MVP) currently trades at A$0.4000, while our model-based Fair Value estimate is A$0.4400 — implying the stock looks roughly 10.0% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
Over the trailing twelve months, Medical Developments International Limited generated revenue of A$40.6M at a net margin of -1.1%. Revenue grew 7.9% year over year. It earns a return on equity of -0.8%. The balance sheet holds a net cash position of A$15.8M. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Medical Developments International Limited manufactures and distributes emergency medical solutions in Australia, Asia, Europe, the United States, and internationally. The company operates through Pain Management and Respiratory segments. It offers Penthrox, a trauma and emergency pain relief product for use in hospitals, emergency departments, ambulance services, sport medicines, and for analgesia during short procedures. The company also distributes asthma and chronic obstructive pulmonary disease products, such space chambers, peak flow meters, portable nebulisers, and silicon face mask. Medical Developments International Limited was founded in 1972 and is headquartered in Scoresby, Australia.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Medical Developments International Limited reported revenue of A$39.1M in FY2025 versus A$25.3M in FY2021, a compound +11.5%/yr. Reported net income was A$94.0K in FY2025.
Open the full interactive analysis →
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥47.08 | ¥26.59 | -44% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,786 | ₹991.46 | -44% |
| Zoetis Inc Z1TS34 | R$24.45 | R$6.33 | -74% |
| Hansoh Pharmaceutical Group 3692 | HK$29.30 | HK$23.90 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,639 | ₹1,281 | -81% |
| Swedish Orphan Biovitrum AB SOBI | kr 446.60 | kr 234.19 | -48% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Medical Developments International Limited (MVP) undervalued?
What is the fair value of MVP?
What is the quality score of MVP?
What is the revenue of Medical Developments International Limited (MVP)?
What is the net profit margin of MVP?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.